Derfor bør den behandlende læge vurdere de potentielle fordele og risici forbundet med at fortsætte behandlingen hos patienter, som ikke udviser hæmatologisk og/ eller klinisk forbedring efter 2 behandlingscykler.
Therefore, the potential benefit and risks associated with continued therapy in patients who do not show haematological and/ or clinical improvement after 2 treatment cycles should be assessed by the treating physician.